Bank of America’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-402,359
| Closed | -$7.46M | – | 8381 |
|
|
2023
Q3 | $7.46M | Buy |
402,359
+106,423
| +36% | +$1.2M | ﹤0.01% | 3021 |
|
|
2023
Q2 | $3.27M | Sell |
295,936
-74,882
| -20% | -$1.04M | ﹤0.01% | 3779 |
|
|
2023
Q1 | $4.98M | Sell |
370,818
-156,871
| -30% | -$2.71M | ﹤0.01% | 3551 |
|
|
2022
Q4 | $6.53M | Buy |
527,689
+84,526
| +19% | +$1.2M | ﹤0.01% | 3135 |
|
|
2022
Q3 | $6.18M | Buy |
443,163
+113,567
| +34% | +$1.83M | ﹤0.01% | 3107 |
|
|
2022
Q2 | $4.55M | Sell |
329,596
-92,844
| -22% | -$1.49M | ﹤0.01% | 3504 |
|
|
2022
Q1 | $6.87M | Buy |
422,440
+43,380
| +11% | +$679K | ﹤0.01% | 3283 |
|
|
2021
Q4 | $6.17M | Buy |
379,060
+170,116
| +81% | +$2.87M | ﹤0.01% | 3433 |
|
|
2021
Q3 | $3.1M | Sell |
208,944
-28,475
| -12% | -$456K | ﹤0.01% | 4034 |
|
|
2021
Q2 | $4.74M | Buy |
237,419
+775
| +0.3% | +$15.4K | ﹤0.01% | 3558 |
|
|
2021
Q1 | $5.46M | Buy |
236,644
+31,355
| +15% | +$874K | ﹤0.01% | 3310 |
|
|
2020
Q4 | $5.07M | Buy |
205,289
+11,541
| +6% | +$382K | ﹤0.01% | 3117 |
|
|
2020
Q3 | $8.03M | Sell |
193,748
-30,077
| -13% | -$1.38M | ﹤0.01% | 2462 |
|
|
2020
Q2 | $10.7M | Buy |
223,825
+55,366
| +33% | +$4.28M | ﹤0.01% | 2157 |
|
|
2020
Q1 | $10.6M | Sell |
168,459
-9,397
| -5% | -$844K | ﹤0.01% | 2016 |
|
|
2019
Q4 | $22M | Buy |
177,856
+58,651
| +49% | +$5.25M | ﹤0.01% | 1801 |
|
|
2019
Q3 | $7.91M | Sell |
119,205
-10,494
| -8% | -$705K | ﹤0.01% | 2762 |
|
|
2019
Q2 | $10.3M | Sell |
129,699
-123,680
| -49% | -$11.1M | ﹤0.01% | 2523 |
|
|
2019
Q1 | $28.3M | Buy |
253,379
+156,837
| +162% | +$17.1M | ﹤0.01% | 1543 |
|
|
2018
Q4 | $9.73M | Buy |
96,542
+6,378
| +7% | +$661K | ﹤0.01% | 2328 |
|
|
2018
Q3 | $11.4M | Sell |
90,164
-35,942
| -29% | -$3.8M | ﹤0.01% | 2359 |
|
|
2018
Q2 | $10.6M | Sell |
126,106
-2,203
| -2% | -$161K | ﹤0.01% | 2404 |
|
|
2018
Q1 | $7.89M | Buy |
128,309
+31,316
| +32% | +$1.89M | ﹤0.01% | 2637 |
|
|
2017
Q4 | $5.67M | Sell |
96,993
-248,245
| -72% | -$15.7M | ﹤0.01% | 3003 |
|
|
2017
Q3 | $20M | Buy |
345,238
+39,491
| +13% | +$4.25M | ﹤0.01% | 1873 |
|
|
2017
Q2 | $37M | Sell |
305,747
-214
| -0.1% | -$24.8K | 0.01% | 1233 |
|
|
2017
Q1 | $34.6M | Sell |
305,961
-60,106
| -16% | -$7.02M | 0.01% | 1289 |
|
|
2016
Q4 | $39.8M | Sell |
366,067
-39,462
| -10% | -$4.7M | 0.01% | 1167 |
|
|
2016
Q3 | $66.7M | Sell |
405,529
-45,456
| -10% | -$7.17M | 0.01% | 822 |
|
|
2016
Q2 | $64.3M | Buy |
450,985
+35,006
| +8% | +$5.1M | 0.01% | 838 |
|
|
2016
Q1 | $53.4M | Buy |
415,979
+13,467
| +3% | +$1.59M | 0.01% | 902 |
|
|
2015
Q4 | $60.1M | Buy |
402,512
+82,669
| +26% | +$14M | 0.01% | 900 |
|
|
2015
Q3 | $53M | Buy |
319,843
+217,617
| +213% | +$47.9M | 0.01% | 939 |
|
|
2015
Q2 | $24.7M | Buy |
102,226
+12,877
| +14% | +$3.43M | 0.01% | 1252 |
|
|
2015
Q1 | $25.2M | Buy |
89,349
+13,094
| +17% | +$2.84M | 0.01% | 1198 |
|
|
2014
Q4 | $11.9M | Sell |
76,255
-7,715
| -9% | -$1.42M | ﹤0.01% | 1787 |
|
|
2014
Q3 | $19.9M | Sell |
83,970
-2,849
| -3% | -$726K | 0.01% | 1404 |
|
|
2014
Q2 | $20.5M | Buy |
86,819
+22,658
| +35% | +$5.97M | 0.01% | 1380 |
|
|
2014
Q1 | $21.2M | Buy |
64,161
+29,652
| +86% | +$10M | 0.01% | 1254 |
|
|
2013
Q4 | $2.36M | Buy |
34,509
+23,775
| +221% | +$1.37M | ﹤0.01% | 3166 |
|
|
2013
Q3 | $741K | Sell |
10,734
-2,035
| -16% | -$100K | ﹤0.01% | 4243 |
|
|
2013
Q2 | $572K | Buy |
+12,769
| New | +$436K | ﹤0.01% | 4620 |
|
Bank of America's ICPT Position: Q4 2023 in Review
Bank of America sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 402,359 shares — an estimated $7.46M sold.
Bank of America first reported a position in ICPT in Q2 2013 and held it in 42 quarters. The position peaked at $66.7M in Q3 2016. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- Bank of America reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Bank of America sold 402,359 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $7.46M.
- Bank of America first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 42 quarters.
- Bank of America's Intercept Pharmaceuticals, Inc. position peaked at $66.7M in Q3 2016.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on Bank of America's 13F filing for Q4 2023, filed 14 Feb 2024.